Awards Presented During the 56th Annual Meeting of the American Society of Hematology
Norwalk, CT, December 15, 2014 – The Multiple Myeloma Research Foundation (MMRF) announced at the ASH Annual Meeting the recipients of its three awards for outstanding acceleration, innovation and collaboration to advance the research and development of novel therapies for multiple myeloma. Each year, the MMRF recognizes the exceptional work of its partners from industry and academia who have played a critical role toward fulfilling the mission of the MMRF: to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. For the year of 2014, the MMRF recognized:
- The Tisch Cancer Institute at The Mount Sinai Health System with the MMRF Innovator Award;
- Winship Cancer Institute at Emory University and The University of Chicago with the MMRF Accelerator Award; and
- Millennium the Takeda Oncology Company with the MMRF Collaborator Award.
“The commitment and dedication of our academic and industry partners to work together on innovative research models and programs is essential in making meaningful progress to improve and extend the lives of people with this devastating disease,” said Walter M. Capone, CEO and President of the MMRF. “On behalf of the entire MMRF and MMRC staff, our Board of Directors and the patients for whom we all work so urgently, thank you to this year’s MMRF Award recipients for your tireless dedication and critical scientific achievements.”
MMRF Innovator Award
The MMRF Innovator Award recognizes Sundar Jagannath, MD and his team from The Tisch Cancer Institute at The Mount Sinai Health System for their extraordinary commitment to innovation in driving new treatment options as a means to improve outcomes for multiple myeloma patients. The Institute was selected for its leadership in research on immunotherapy in multiple myeloma, collaborations with the Translational Network and exemplary work on the landmark CoMMpass Study™.
MMRF Accelerator Award
The MMRF Accelerator Award recognizes Sagar Lonial, MD and his team from the Winship Cancer Institute of Emory University and Andrzej Jakubowiak, MD, PhD and his team from the University of Chicago. Both teams were recognized for their outstanding efforts and exceptional contributions to the rapid completion of clinical trials supported through the Multiple Myeloma Research Consortium (MMRC), and for their demonstrated leadership as members of the Consortium.
MMRF Collaborator Award
The MMRF Collaborator Award recognizes Millennium the Takeda Oncology Company for its outstanding commitment to collaboration as a means to advance the research and development of new, effective treatments for patients with multiple myeloma. Millennium the Takeda Oncology Company was selected for its continuous support of MMRF programs throughout the years, including the CoMMpass Study™ and the MMRC Tissue Bank.
The MMRF and MMRC would like to thank all research institutions and industry partners for their outstanding accomplishments and collaborative efforts in 2014.
About the CoMMpass Study™
CoMMpass is a longitudinal study of patients with newly-diagnosed active multiple myeloma. The goal is to map the genomic profile of each patient to clinical outcomes to develop a more complete understanding of patient responses to treatments. A cornerstone of the MMRF’s Personalized Medicine Initiative, the study will collect and analyze tissue samples and genetic information from approximately 1,000 newly diagnosed multiple myeloma patients for at least eight years.
About Multiple Myeloma (MM)
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 24,050 adults (13,500 men and 10,550 women) in the United States will be diagnosed with MM in 2014 and an estimated 11,090 people are predicted to die from the disease. The five-year survival rate for MM is approximately 43%, versus 28% in 1998.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised $275 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.
About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)(3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University’s Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Mount Sinai School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University in St. Louis. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.